Rathbones Group PLC Buys 12,639 Shares of IDEXX Laboratories, Inc. $IDXX

Rathbones Group PLC boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 11.6% in the first quarter, HoldingsChannel reports. The firm owned 121,511 shares of the company’s stock after acquiring an additional 12,639 shares during the period. Rathbones Group PLC’s holdings in IDEXX Laboratories were worth $68,276,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in IDXX. SHP Wealth Management acquired a new position in shares of IDEXX Laboratories during the 4th quarter worth about $26,000. Virtus Advisers LLC bought a new position in IDEXX Laboratories during the 3rd quarter worth approximately $26,000. Mowery & Schoenfeld Wealth Management LLC grew its holdings in IDEXX Laboratories by 58.8% during the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the period. Wormser Freres Gestion increased its stake in IDEXX Laboratories by 671.4% in the fourth quarter. Wormser Freres Gestion now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 47 shares in the last quarter. Finally, WealthCollab LLC bought a new position in shares of IDEXX Laboratories during the second quarter worth $30,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $559.07 on Monday. The company has a market cap of $44.10 billion, a price-to-earnings ratio of 41.17, a P/E/G ratio of 3.06 and a beta of 1.54. The firm has a 50-day moving average of $557.36 and a 200-day moving average of $589.46. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the business earned $2.91 earnings per share. IDEXX Laboratories’s quarterly revenue was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on IDXX. Weiss Ratings upgraded shares of IDEXX Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Wednesday. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. UBS Group dropped their target price on shares of IDEXX Laboratories from $640.00 to $620.00 and set a “neutral” rating on the stock in a report on Monday, July 27th. Finally, Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $749.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.